Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Topical eye treatment with JGRi1, a protein/protein interaction inhibitor, mitigates retinal degeneration.

Cell death & disease·2026
Same author

Oxidative Stress Signaling and Regenerative Responses in a Larval Zebrafish Model of Retinal Light Damage.

Antioxidants (Basel, Switzerland)·2026
Same author

Chronic fasudil treatment induces benzodiazepine-like tolerance via modulation of GABA-A receptor γ2 subunit expression and impairs contextual fear memory in mice.

Pharmacological reports : PR·2026
Same author

Hormetic Effects of Curcumin in RPE Cells: SIRT1 and Caspase-3 Inactivation with Implications for AMD.

International journal of molecular sciences·2025
Same author

miR-92a-3p and miR-320a are Upregulated in Plasma Neuron-Derived Extracellular Vesicles of Patients with Frontotemporal Dementia.

Molecular neurobiology·2024
Same author

Molecular mechanism and potential therapeutic targets of necroptosis and ferroptosis in Alzheimer's disease.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2023

Related Experiment Video

Updated: Jul 23, 2025

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

3.8K

Retinoprotective compounds, current efficacy, and future prospective.

Rachele Marino1, Rebecca Sappington2, Marco Feligioni3

  • 1Laboratory of Neuronal Cell Signaling, EBRI Rita Levi-Montalcini Foundation, Rome, Italy.

Neural Regeneration Research
|July 14, 2023
PubMed
Summary
This summary is machine-generated.

Vision loss from retinal disorders like diabetic retinopathy and glaucoma is increasing. Current treatments manage symptoms but do not cure these conditions, highlighting the need for novel approaches.

Keywords:
age-related macular degenerationanti-inflammatory drugsantioxidantsdiabetic retinopathyglaucomaneuroprotective compoundsretinitis pigmentosaretinopathiesvision loss

More Related Videos

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

4.6K
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K

Related Experiment Videos

Last Updated: Jul 23, 2025

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

3.8K
Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

4.6K
Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
07:49

Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions

Published on: September 17, 2014

11.6K

Area of Science:

  • Ophthalmology and Vision Science
  • Molecular Medicine
  • Neuroscience

Background:

  • Retinal dysfunction causes significant vision loss in prevalent disorders such as diabetic retinopathy, age-related macular degeneration, glaucoma, and retinitis pigmentosa.
  • These retinopathies are increasing globally, exacerbated by rising life expectancy and multifactorial causes including molecular changes, environmental factors, and genetic predisposition.
  • Current treatments offer symptomatic relief by managing intraocular pressure, inflammation, and oxidative stress, but do not provide cures for these progressive conditions.

Purpose of the Study:

  • To review current market treatments for major retinopathies.
  • To highlight emerging treatments currently in clinical trials.
  • To explore the potential of precision medicine approaches for tailored retinopathies treatment.

Main Methods:

  • Literature review of existing and investigational treatments for common retinopathies.
  • Analysis of molecular mechanisms underlying retinal dysfunction and neurodegeneration.
  • Discussion of advanced diagnostic and therapeutic technologies, including gene therapy and metabolomics.

Main Results:

  • Existing treatments primarily focus on symptom management (e.g., anti-inflammatories, antioxidants) and do not halt disease progression.
  • Several novel therapeutic strategies are under investigation in clinical trials, offering potential for more effective interventions.
  • Advancements in diagnostic methods enable a precision medicine approach to identify specific molecular pathways for personalized treatment.

Conclusions:

  • There is a critical unmet need for curative treatments for widespread retinal disorders.
  • Emerging therapies and precision medicine, utilizing technologies like gene therapy, hold promise for transforming patient outcomes.
  • Future research should focus on developing targeted treatments based on individual molecular profiles to combat retinal dysfunction.